The group’s principal activities include discovering and developing human monoclonal antibodies to treat a variety of serious diseases. The group was founded in 1997. The group patented ACTIVMAb(R) technology allows for the direct selection of high affinity, fully human monoclonal antibodies. The group operates from the United States.